Results 51 to 60 of about 15,537,279 (243)
Reasons for potential exclusion from implementation of targeted temperature management of study patients.
Ping-Hsun Yu (3335550) +6 more
core +1 more source
Targeted temperature management in cardiac arrest: survival evaluated by propensity score matching [PDF]
Background: Targeted temperature management in cardiac arrest was introduced following evidence of increased survival from two controlled trials published in 2002.
Eirik A. Buanes +9 more
core +1 more source
Supplemental Material for Implementing a Stepwise Shivering Protocol During Targeted Temperature Management by Czarina A. Bock, Whitney G. Medford, Emily Coughlin, Rahul Mhaskar, and Katlynd M.
Rahul Mhaskar (302539) +4 more
core +1 more source
Background: Prolonged length of stay (LOS) following targeted temperature management (TTM) administered after cardiac arrest may affect healthcare plans and expenditures.
Wei-Ting Chiu +9 more
doaj +1 more source
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Additional file 1: Clinical and biological variables during targeted temperature management; details of outliers; Mxa values comparison among CPC groups; regularized regression models with elastic net; changes in Mxa according to the phase of temperature
Ilaria Alice Crippa (11609981) +9 more
core +1 more source
Meta-analysis of targeted temperature management in animal models of cardiac arrest
Background Targeted temperature management (TTM) of 32 to 34 °C has been the standard treatment for out-of-hospital cardiac arrest since clinical trials in 2002 indicated benefit on survival and neurological outcome.
Hilmer Olai +8 more
doaj +1 more source
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir +9 more
wiley +1 more source
Targeted temperature management following cardiac arrest. A systematic review
Líkamshitastjórnun er meðferð sem notuð er í kjölfar endurlífgunar vegna hjartastopps. Rannsóknir eru misvísandi um hvaða kjarnlíkamshita á að miða við. Evrópska endurlífgunarráðið (ERC) mælir með að hjartastopps sjúklingar séu kældir niður í 32°C til 36°
Hrefna Björk Jónsdóttir 1993-
core +2 more sources
Targeted Temperature Management After Cardiac Arrest: The Montreal Heart Institute Experience
Background: Targeted temperature management (TTM) has been associated with an improvement in neurological function and survival in patients with cardiac arrest (CA) and an initially shockable rhythm.
Nadia Boulé-Laghzali, MD +9 more
doaj +1 more source

